IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia (NCT04086264)

🧪 Interventions in This Study

• Azacitidine (DRUG)
• IMGN632 (DRUG)
• Venetoclax (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (29 Sites)

Showing the first 25 of 29 sites.

• City of Hope National Medical Center /ID# 269273 — Duarte, California
• University Of California Irvine Medical Center /ID# 269275 — Orange, California
• Moffitt Cancer Center /ID# 269269 — Tampa, Florida
• Northwestern University- Robert H. Lurie Comprehensive Cancer Center /ID# 269642 — Chicago, Illinois
• Dana-Farber Cancer Institute /ID# 269267 — Boston, Massachusetts
• University of Michigan /ID# 269079 — Ann Arbor, Michigan
• Mayo Clinic Hospital Rochester /ID# 269643 — Rochester, Minnesota
• Roswell Park Cancer Institute /ID# 269266 — Buffalo, New York
• New York Presbyterian Hospital Weill Cornell Medical Center /ID# 269271 — New York, New York
• Duke University Health System /ID# 269268 — Durham, North Carolina
• Cleveland Clinic - Cleveland /ID# 269272 — Cleveland, Ohio
• MD Anderson Houston /ID# 269265 — Houston, Texas
• Fred Hutchinson Cancer Research Center /ID# 269270 — Seattle, Washington
• Institut Paoli-Calmettes /ID# 269080 — Marseille, Bouches-du-Rhone
• IUCT Oncopole /ID# 269284 — Toulouse, Occitanie
• Hôpital Saint-Louis /ID# 269282 — Paris, Paris
• Centre Antoine-Lacassagne /ID# 269285 — Nice, Provence-Alpes-Côte d'Azur Region
• Hospices Civils de Lyon - Centre Hospitalier Lyon-Sud /ID# 269286 — Pierre-Bénite, Rhone
• Centre Hospitalier de Versailles André Mignot /ID# 269287 — Le Chesnay,
• Universitaetsklinikum Ulm /ID# 269686 — Ulm, Baden-Wurttemberg
• Universitaetsklinikum Muenster /ID# 269688 — Münster, North Rhine-Westphalia
• Universitaetsklinikum Leipzig /ID# 269682 — Leipzig, Saxony
• IRCCS AOU di Bologna Policlinico Sant Orsola Malpighi /ID# 269281 — Bologna, Bologna
• Istituto Europeo Di Oncologia /ID# 269646 — Milan, Milano
• Azienda Ospedaliero Universitaria Maggiore Della Carità /ID# 269280 — Novara, Novara

📞 Contact the Study Coordinator

Phone: (800) 826-4673

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Acute Myeloid Leukemia

• PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS — Tampa, Florida
• Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCT — Tampa, Florida
• Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy — Little Rock, Arkansas
• Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia — Burbank, California
• A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies — Duarte, California
• A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia — Madera, California

Explore by condition: All Acute Myeloid Leukemia clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.